Biotechnology

Equity ETFs

Biotech ETFs Rip Higher to Start 2019

By Brenton GarenJanuary 14, 2019

Equity ETFs

Biotech ETFs Surge After Eli Lilly Buys Out Loxo Oncology

By Max ChenJanuary 7, 2019

Equity ETFs

Biotech ETFs Pop as Bristol-Myers Squibb Set to Acquire Celgene

By Max ChenJanuary 3, 2019

Webcasts

An ETF to Capture Biotech’s Breakthrough of the Century

By Max ChenDecember 4, 2018

Webcasts

The Power of Genome Editing: What Investors Should Know

By Max ChenDecember 3, 2018

Equity ETFs

Pharmaceutical ETFs Could Maintain Their Momentum

By Max ChenSeptember 6, 2018

New ETFs

Loncar Debuts ETF to Play China’s Biotech, Pharma Companies

By Max ChenAugust 15, 2018

Equity ETFs

Biotech ETFs Rally as Illumina Tops Q2 Expectations

By Max ChenJuly 31, 2018

Equity ETFs

Biotech ETFs Climb on Biogen’s Promising Clinical Trial

By Max ChenJuly 6, 2018

Equity ETFs

Sarepta Therapeutics Helps Biotech ETFs Buck Market Trend

By Max ChenJune 19, 2018

Robotics & AI

The Mind Controlled Bionic Arm

By Tom LydonJune 5, 2018

Webcasts

An ETF to Capture Genomic Sequencing Innovation

By Max ChenMay 15, 2018

Webcasts

As Genome-Editing Evolves, So Do The Investment Opportunities

By Max ChenMay 14, 2018

Equity ETFs

6 Top Healthcare ETFs Rally as Trump Vows End to ‘Global Freeloading’

By Max ChenMay 11, 2018

Equity ETFs

Healthcare ETFs Lag Markets as Celgene Drags

By Max ChenApril 30, 2018

Equity ETFs

Big Biotech ETF Can Bounce Back

By Tom LydonApril 18, 2018

Equity ETFs

Catalysts Abound for Biotech ETFs

By Tom LydonApril 10, 2018

Equity ETFs

Alkermes FDA Refusal: Biotech ETFs Dragged Down

By Max ChenApril 2, 2018